Latest Lead News

Steadfast Group reported a robust FY25 with underlying NPAT rising 17.2% to $295.5 million, driven by strong organic growth and strategic acquisitions in the US and UK. The insurer broker continues to invest in technology and international expansion while raising dividends.

Sparc Technologies reported a narrower FY25 loss alongside progress in green hydrogen and graphene additive projects, supported by government grants and a successful capital raise.

ARC Funds Limited posted a $2.45 million loss for FY2025, driven by strategic investments and increased transaction costs as it expands its funds management platform.

CTI Logistics Limited has announced a fully franked ordinary dividend of AUD 0.055 per share for the half-year ending June 2025, offering shareholders reinvestment and bonus security plans with attractive discounts.

NEXTDC’s FY25 results reveal robust financial growth driven by surging AI and cloud demand, alongside a strategic joint venture to expand its Western Sydney data centre footprint.

NEXTDC Limited reported a 6% rise in FY25 revenue and underlying EBITDA, offset by a widened loss due to a $2.9 billion debt refinancing. The company’s strategic expansion in AI-ready data centres and a strengthened $6.4 billion debt facility position it for significant growth.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.

HPP has agreed to acquire Red Earth Energy Storage in a $40 million merger, aiming to relist on the ASX by early 2026 and capitalize on Australia’s growing battery storage market.

Mad Paws Holdings reported a 14% revenue increase and improved EBITDA margins in FY25, while preparing to sell its marketplace business to Rover Group and exit e-commerce operations.

Wiseway Group has reported a striking 66% increase in revenue for FY25, driven by robust expansion in its Imports and Overseas divisions alongside a nearly sevenfold rise in net profit before tax.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.